Pharmaron Beijing Co., Ltd.

SZSE:300759 Stock Report

Market Cap: CN¥43.0b

Pharmaron Beijing Valuation

Is 300759 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300759 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300759 (CN¥26.68) is trading below our estimate of fair value (CN¥27.65)

Significantly Below Fair Value: 300759 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300759?

Key metric: As 300759 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300759. This is calculated by dividing 300759's market cap by their current earnings.
What is 300759's PE Ratio?
PE Ratio25.2x
EarningsCN¥1.88b
Market CapCN¥43.05b

Price to Earnings Ratio vs Peers

How does 300759's PE Ratio compare to its peers?

The above table shows the PE ratio for 300759 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.7x
300347 Hangzhou Tigermed Consulting
54.8x35.5%CN¥48.7b
603259 WuXi AppTec
17.6x15.4%CN¥139.3b
688131 Shanghai Haoyuan Chemexpress
52.4x37.9%CN¥8.0b
688046 GemPharmatech
38.1x27.9%CN¥5.3b
300759 Pharmaron Beijing
25.2x7.0%CN¥43.4b

Price-To-Earnings vs Peers: 300759 is good value based on its Price-To-Earnings Ratio (25.2x) compared to the peer average (40.7x).

Price to Earnings Ratio vs Industry

How does 300759's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
300759 25.2xIndustry Avg. 32.7xNo. of Companies6PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300759 is good value based on its Price-To-Earnings Ratio (25.2x) compared to the Asian Life Sciences industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is 300759's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300759 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.2x
Fair PE Ratio25.6x

Price-To-Earnings vs Fair Ratio: 300759 is good value based on its Price-To-Earnings Ratio (25.2x) compared to the estimated Fair Price-To-Earnings Ratio (25.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300759 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥26.68
CN¥28.62
+7.3%
31.6%CN¥38.00CN¥8.20n/a11
Nov ’25CN¥28.79
CN¥27.14
-5.7%
30.3%CN¥38.00CN¥8.20n/a12
Oct ’25CN¥30.35
CN¥23.51
-22.5%
26.0%CN¥31.00CN¥8.20n/a12
Sep ’25CN¥19.99
CN¥22.63
+13.2%
30.0%CN¥31.00CN¥8.20n/a12
Aug ’25CN¥22.06
CN¥22.71
+2.9%
29.9%CN¥31.41CN¥9.10n/a11
Jul ’25CN¥18.57
CN¥22.71
+22.3%
29.9%CN¥31.41CN¥9.10n/a11
Jun ’25CN¥20.64
CN¥24.15
+17.0%
33.4%CN¥40.00CN¥9.10n/a12
May ’25CN¥19.75
CN¥24.15
+22.3%
33.4%CN¥40.00CN¥9.10n/a12
Apr ’25CN¥21.01
CN¥29.29
+39.4%
34.3%CN¥40.00CN¥9.10n/a11
Mar ’25CN¥23.23
CN¥33.84
+45.7%
35.7%CN¥61.24CN¥17.40n/a11
Feb ’25CN¥21.27
CN¥33.84
+59.1%
35.7%CN¥61.24CN¥17.40n/a11
Jan ’25CN¥28.98
CN¥35.87
+23.8%
32.4%CN¥61.24CN¥17.71n/a11
Dec ’24CN¥33.14
CN¥37.14
+12.1%
32.3%CN¥61.24CN¥17.71n/a11
Nov ’24CN¥32.69
CN¥36.51
+11.7%
32.4%CN¥61.24CN¥17.79CN¥28.7911
Oct ’24CN¥31.10
CN¥35.11
+12.9%
36.5%CN¥66.94CN¥17.79CN¥30.3511
Sep ’24CN¥29.44
CN¥34.91
+18.6%
37.5%CN¥66.94CN¥15.60CN¥19.9911
Aug ’24CN¥28.32
CN¥37.73
+33.2%
28.6%CN¥56.67CN¥14.38CN¥22.0611
Jul ’24CN¥25.52
CN¥40.40
+58.3%
30.4%CN¥64.09CN¥25.33CN¥18.5711
Jun ’24CN¥32.21
CN¥41.89
+30.0%
28.4%CN¥64.09CN¥25.33CN¥20.6410
May ’24CN¥32.64
CN¥41.89
+28.3%
28.4%CN¥64.09CN¥25.33CN¥19.7510
Apr ’24CN¥32.65
CN¥48.69
+49.2%
36.2%CN¥73.33CN¥24.88CN¥21.019
Mar ’24CN¥40.38
CN¥51.97
+28.7%
29.0%CN¥73.33CN¥25.33CN¥23.239
Feb ’24CN¥48.51
CN¥56.87
+17.2%
41.1%CN¥114.00CN¥26.67CN¥21.2710
Jan ’24CN¥45.33
CN¥56.07
+23.7%
42.3%CN¥114.00CN¥26.67CN¥28.9810
Dec ’23CN¥44.42
CN¥56.07
+26.2%
42.3%CN¥114.00CN¥26.67CN¥33.1410
Nov ’23CN¥38.50
CN¥55.88
+45.1%
43.6%CN¥114.00CN¥24.00CN¥32.6911

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

7D

-1.4%

1Y

-24.4%

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.05

7D

3.7%

1Y

7.9%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

7D

-1.8%

1Y

13.3%